Advanced search
Publication Cover
Expert Review of Vaccines Volume 21, 2022 - Issue 2
Submit an article Journal homepage
366
Views
32
CrossRef citations to date
0
Altmetric
Original Research

Willingness to receive a booster dose of inactivated coronavirus disease 2019 vaccine in Taizhou, China

Tao-Hsin Tunga Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, ChinaORCID Iconhttps://orcid.org/0000-0003-2097-8375
ORCID Icon,
Xiao-Qing Linb Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, ChinaORCID Iconhttps://orcid.org/0000-0003-4986-2835
ORCID Icon,
Yan Chenb Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, ChinaORCID Iconhttps://orcid.org/0000-0002-4975-989X
ORCID Icon,
Mei-Xian Zhanga Evidence-based Medicine Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6538-7037
ORCID Icon &
Jian-Sheng Zhub Department of Infectious Diseases, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, ChinaCorrespondence[email protected]
Pages 261-267 | Received 14 Nov 2021, Accepted 07 Dec 2021, Published online: 22 Dec 2021

References

  • Tsang HF, Chan LWC, Cho WCS, et al. An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies. Expert Rev Anti Infect Ther. 2021;19(7):877–888.
  • Keni R, Alexander A, Nayak PG, et al. COVID-19: emergence, spread, possible treatments, and global burden. Front Public Health. 2020;8:216.
  • Vaishya R, Sibal A, Malani A, et al. SARS-CoV-2 infection after COVID-19 immunization in healthcare workers: a retrospective, pilot study. Indian J Med Res. 2021;153(5):550–554.
  • Bergwerk M, Gonen T, Lustig Y, et al., Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 385(16): 1474–1484. 2021.
  • Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51.
  • Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA. 2021;326(1):35–45.
  • Zhang Y, Zeng G, Pan H, et al., Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 21(2): 181–192. 2021.
  • Tanriover MD, Doğanay HL, Akova M, et al. CoronaVac study group. efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222.
  • Jara A, Undurraga EA, González C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in chile. N Engl J Med. 2021;385(10):875–884.
  • Li XN, Huang Y, Wang W, et al., Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Emerg Microbes Infect. 10(1): 1751–1759. 2021.
  • Duarte LF, Gálvez NMS, Iturriaga C, et al. Immune profile and clinical outcome of breakthrough cases after vaccination with an inactivated SARS-CoV-2 vaccine. Front Immunol. 2021;12:742914.
  • Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021; 10: 100208.
  • Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75(7):1564–1581.
  • Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther. 2020;5(1):237.
  • Jalkanen P, Kolehmainen P, Häkkinen HK, et al., COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 12(1): 3991. 2021.
  • Apisarnthanarak A, Nantapisal S, Pienthong T, et al. Healthcare-associated transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) among Thai healthcare personnel who receive 2 doses of a coronavirus disease 2019 (COVID-19) vaccine: a call for considering a booster dose. Infect Control Hosp Epidemiol. 2021;1–2.
  • Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881–891.
  • Ramasamy MN, Minassian AM, Ewer KJ, et al., Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 396(10267): 1979–1993. 2021.
  • Yigit M, Ozkaya-Parlakay A, Cosgun Y, et al. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience. J Med Virol. 2021;94(1):287–290.
  • Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines (Basel). 2021;9(2):160.
  • Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
  • Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416.
  • Yeh M-Y, Wu S-C, Tung T-H. The relation between patient education, patient empowerment and patient satisfaction: a cross-sectional-comparison study. Appl Nurs Res. 2018;39:11–17.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.